Haemonetics Co. (NYSE:HAE) Stake Lifted by Riverwater Partners LLC

Riverwater Partners LLC boosted its stake in Haemonetics Co. (NYSE:HAE) by 185.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,841 shares of the medical instruments supplier’s stock after purchasing an additional 29,109 shares during the quarter. Haemonetics comprises 1.8% of Riverwater Partners LLC’s portfolio, making the stock its 10th largest position. Riverwater Partners LLC’s holdings in Haemonetics were worth $3,556,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its holdings in shares of Haemonetics by 14.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 191,253 shares of the medical instruments supplier’s stock worth $16,354,000 after buying an additional 24,394 shares during the last quarter. Vanguard Group Inc. increased its position in Haemonetics by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock worth $462,293,000 after purchasing an additional 25,451 shares in the last quarter. Dynamic Advisor Solutions LLC increased its position in Haemonetics by 2.1% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 18,300 shares of the medical instruments supplier’s stock worth $1,562,000 after purchasing an additional 374 shares in the last quarter. Cardinal Capital Management raised its holdings in Haemonetics by 26.5% in the first quarter. Cardinal Capital Management now owns 14,283 shares of the medical instruments supplier’s stock valued at $1,219,000 after buying an additional 2,994 shares during the period. Finally, AlphaMark Advisors LLC acquired a new position in Haemonetics during the first quarter valued at approximately $304,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Down 1.6 %

Shares of NYSE HAE opened at $73.29 on Thursday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The stock’s 50-day simple moving average is $75.67 and its 200-day simple moving average is $83.35. The firm has a market cap of $3.73 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 1.19 and a beta of 0.30.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The business had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. During the same quarter last year, the business earned $1.05 EPS. Haemonetics’s revenue for the quarter was up 8.0% compared to the same quarter last year. As a group, equities analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on HAE shares. Citigroup dropped their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Bank of America began coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective on the stock. CL King began coverage on Haemonetics in a research report on Friday, September 13th. They issued a “buy” rating and a $116.00 target price for the company. Finally, BTIG Research started coverage on Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $106.14.

Insider Buying and Selling

In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares in the company, valued at $1,658,565.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.80% of the company’s stock.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.